{"id":77558,"date":"2024-03-12T14:28:24","date_gmt":"2024-03-12T19:28:24","guid":{"rendered":"https:\/\/equitynewsreport.com\/illumina-shares-fall-as-ichan-reportedly-abandons-second-proxy-contest\/"},"modified":"2024-03-12T14:28:24","modified_gmt":"2024-03-12T19:28:24","slug":"illumina-shares-fall-as-ichan-reportedly-abandons-second-proxy-contest","status":"publish","type":"post","link":"https:\/\/equitynewsreport.com\/h\/illumina-shares-fall-as-ichan-reportedly-abandons-second-proxy-contest\/","title":{"rendered":"Illumina shares fall as Ichan reportedly abandons second proxy contest"},"content":{"rendered":"<div readability=\"59\">\n<div id=\"imgCarousel\" class=\"imgCarousel\">\n<img decoding=\"async\" alt=\"Illumina shares fall as Ichan reportedly abandons second proxy contest\" id=\"carouselImage\" src=\"https:\/\/i-invdn-com.investing.com\/news\/LYNXNPEAAD140_L.jpg\"><br \/>\n<span class=\"text\">\u00a9 Reuters. <\/span><br \/>\n<i class=\"imgGrad\"><\/i>\n<\/div>\n<p>Investing.com &#8212; Illumina shares fell Tuesday after activist investor Carl Icahn dropped a threat to oust more of the\u00a0DNA sequencing giant&#8217;s board members, walking away from a second proxy contest, Reuters reported, citing unnamed sources.<\/p>\n<p>Illumina Inc (NASDAQ:) was down 4% following the news.<\/p>\n<p>In December, Ichan had threaten to oust more\u00a0Illumina directors in a second proxy battle in as many years, after growing dissatisfied with the\u00a0 board&#8217;s performance including its acquisition of blood test maker grail.\u00a0<\/p>\n<p>Following the\u00a0DNA sequencing giant plan to sell\u00a0grail amid significant regulatory opposition, Icahn now\u00a0sees little value in a new proxy contest, the sourced told Reuters.<\/p>\n<p>Still, Icahn remains intent on persisted with lawsuit he filed against Illumina directors last year, for allegedly breaking their fiduciary duties by acquiring grail despite antitrust concerns from regulators.\u00a0 \u00a0\u00a0<\/p>\n<p>Ichan and\u00a0Illumina declined to comment, Reuters reported.<\/p>\n<p>\u00a0<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u00a9 Reuters. Investing.com &#8212; Illumina shares fell Tuesday after activist investor Carl Icahn dropped a threat to oust more of the\u00a0DNA sequencing giant&#8217;s board members, walking away from a second proxy contest, Reuters reported, citing unnamed sources. Illumina Inc (NASDAQ:) was down 4% following the news. In December, Ichan had threaten to oust more\u00a0Illumina directors in a second proxy battle in as many years, after growing dissatisfied with the\u00a0 board&#8217;s performance including its acquisition of blood test maker grail.\u00a0 Following the\u00a0DNA sequencing giant plan to sell\u00a0grail amid significant regulatory opposition, Icahn now\u00a0sees little value in a new proxy contest, the [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":77559,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[50,48,49,3],"tags":[],"_links":{"self":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts\/77558"}],"collection":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/comments?post=77558"}],"version-history":[{"count":0,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts\/77558\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/media\/77559"}],"wp:attachment":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/media?parent=77558"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/categories?post=77558"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/tags?post=77558"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}